Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02386839 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT02386839 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 76 participants.
The verdict
NCT02386839, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).
Interventions
- DRUG rhIGF-1/rhIGFBP-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2015-03-26 |
| Est. Completion | 2021-09-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02386839
The ClinicalTrials.gov registry entry for NCT02386839 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhIGF-1/rhIGFBP-3 is the first listed.
NCT02386839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02386839 about?
NCT02386839 is a clinical study titled "Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)". The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).
What is the current status of trial NCT02386839?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2015-03-26. Estimated completion is 2021-09-28.
What interventions are being tested in trial NCT02386839?
The interventions under investigation include: rhIGF-1/rhIGFBP-3 (DRUG).
Who is sponsoring clinical trial NCT02386839?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.